Phase I/II study of postoperative adjuvant therapy with Gemcitabine plus peptide vaccine for pancreatic cancer.
Phase 1
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000004332
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1.Pregnancy or lactation 2.Decision of unsuitableness by principal investigatior 3.Patient with severe underlying disease 4.Patient with severe allergy disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of safety Postoperative progression free survival Postoperative overall survival
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Gemcitabine and peptide vaccine synergy in pancreatic cancer immunotherapy?
How does adjuvant Gemcitabine plus peptide vaccine compare to standard-of-care in resected pancreatic cancer outcomes?
Which biomarkers correlate with response to Gemcitabine and peptide vaccine combination in pancreatic cancer?
What adverse events are associated with postoperative Gemcitabine and peptide vaccine therapy for pancreatic cancer?
Are there alternative immunotherapeutic combinations to Gemcitabine plus peptide vaccine in PDAC treatment development?